InSysBio announces its participation in Quantitative Systems Pharmacology Conference (QSPC) 2026 which is to be held from April 8-10, 2026 in Leiden, the Netherlands. InSysBio team is going to present its QSP modeling services & software to optimize drug development at Booth #3 and posters, namely:
Affiliations: (1) InSysBio CY; (2) InSysBio UK; (3) Clinical Pharmacology Pharmacometric Systems and Tools, Platform Sciences, GSK, UK
Moreover, InSysBio will hold a workshop on Heta at Golden Tulip & Tulip Inn Leiden Centre, Leiden, the Netherlands on April 7, 2026, 1 PM – 5 PM. This workshop will introduce an engineering-style approach to QSP modeling using the Heta language and tools. Participants will explore structured and modular model descriptions, improved transparency, and practical workflows that support scalable and reproducible model development.
About InSysBio
InSysBio is a group of Quantitative Systems Pharmacology (QSP) companies located in Limassol, Cyprus (INSYSBIO CY Ltd) and Edinburgh, UK (INSYSBIO UK LIMITED). InSysBio was founded in 2004 and has an extensive track record of helping pharmaceutical companies to make right decisions on the critical stages of drug research and development by application of QSP modeling. InSysBio's cutting-edge QSP approach has already become a part of the drug development process implemented by our strategic partners: there are more than 100 completed projects in collaboration with leaders of pharmaceutical industry and innovative biotech companies. For more information about InSysBio, its solutions and services, visit www.insysbio.com
| ← | November 2022 | → | ||||
| Mo | Tu | We | Th | Fr | Sa | Su |
|---|---|---|---|---|---|---|
|
1
|
2
|
3
|
4
|
5
|
6
| |
|
7
|
8
|
9
1.
09 Nov 2022 13:21
InSysBio to start the operation of new Headquarters and new branch office
InSysBio announces the start of operation of Headquarters in the United Kingdom. At the same time, the new branch office has been founded in Cyprus and part of InSysBio team has relocated there, thus, expanding the company’s presence.
|
10
|
11
|
12
|
13
|
|
14
|
15
|
16
|
17
|
18
|
19
|
20
|
|
21
|
22
|
23
|
24
|
25
|
26
|
27
|
|
28
|
29
|
30
| ||||